# Regenxbio (RGNX) — Earnings

RGNX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rgnx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.43 |
| EPS estimate | $0.08 |
| EPS surprise | +446.38% |
| Revenue surprise | +10.64% |
| Revenue | $108.0M |
| Revenue estimate | $97.6M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1590877/000119312526336725/rgnx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f3783cf5-cbaa-d2a2-b03b-47ac56496e19.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | $0.08 | $0.43 | 446.38% | $97.6M | $108.0M |
| Q1 2026 | May 14, 2026 | −$1.34 | −$1.72 | -28.65% | $25.8M | $6.4M |
| Q4 2025 | Mar 5, 2026 | −$0.88 | −$1.30 | -48.52% | $48.9M | $30.3M |
| Q3 2025 | Nov 6, 2025 | −$1.28 | −$1.20 | 6.37% | $24.8M | $29.7M |
| Q2 2025 | Aug 7, 2025 | −$0.94 | −$1.38 | -47.14% | $38.7M | $21.4M |
| Q1 2025 | May 12, 2025 | $0.46 | $0.12 | -73.93% | $107.9M | $89.0M |
| Q4 2024 | Mar 13, 2025 | −$1.14 | −$1.01 | 11.48% | $23.7M | $21.2M |
| Q3 2024 | Nov 6, 2024 | −$1.12 | −$1.17 | -4.25% | $23.6M | $24.2M |
| Q2 2024 | Aug 1, 2024 | −$1.29 | −$1.05 | 18.70% | $23.0M | $22.3M |
| Q1 2024 | May 8, 2024 | −$1.26 | −$1.38 | -9.60% | $23.5M | $15.6M |
| Q4 2023 | Feb 27, 2024 | −$1.27 | −$1.43 | -12.57% | $34.0M | $22.2M |
| Q3 2023 | Nov 8, 2023 | −$1.46 | −$1.41 | 3.20% | $26.1M | $28.9M |
| Q2 2023 | Aug 2, 2023 | −$1.19 | −$1.66 | -39.90% | $34.5M | $20.0M |
| Q1 2023 | May 3, 2023 | −$1.42 | −$1.53 | -7.69% | $31.2M | $19.1M |
| Q4 2022 | Feb 28, 2023 | −$1.28 | −$1.38 | -7.60% | $37.5M | $31.3M |
| Q3 2022 | Nov 3, 2022 | −$1.47 | −$1.75 | -18.89% | $30.8M | $26.5M |
| Q2 2022 | Aug 3, 2022 | −$1.40 | −$1.58 | -12.46% | $28.3M | $32.6M |
| Q1 2022 | May 4, 2022 | −$1.54 | −$1.79 | -16.30% | $27.2M | $22.2M |
| Q4 2021 | Mar 1, 2022 | $7.69 | $6.67 | -13.29% | $427.8M | $398.7M |
| Q3 2021 | Nov 2, 2021 | −$1.03 | −$1.37 | -32.64% | $33.2M | $30.8M |

## Frequently Asked Questions

### When did Regenxbio (RGNX) last report earnings?

Regenxbio last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did RGNX beat earnings estimates?

Yes. Regenxbio reported EPS of $0.43 for Q2 2026 against a $0.08 estimate — a 446.38% beat.

### How much revenue did RGNX report last quarter?

Regenxbio reported $108.0M in revenue for Q2 2026, against a consensus estimate of $97.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).